NCT00933296

Brief Summary

The Schnitzler syndrome is a rare entity characterized by an urticarial rash and recurrent fever in a patient with a monoclonal IgM component. Other frequent signs include joint, bone and muscle pain, enlarged spleen, liver and lymph nodes, increased blood sedimentation rate (BSR), elevated neutrophil count and abnormalities on bone morphologic investigations. In 2001, the investigators proposed criteria to diagnose this syndrome, which are currently admitted in the literature. The main complications of the Schnitzler syndrome are a difficult-to-control inflammatory anemia, AA-amyloidosis and malignant B lymphoproliferative disorders. About 15% of patients with a Schnitzler will eventually develop a lymphoproliferative disorder; thus this syndrome allows studying the relationship between lymphomagenesis and inflammation. By many aspects, the Schnitzler syndrome is reminiscent of auto-inflammatory syndromes. Though the term auto-inflammatory disease is as to yet restricted to diseases with Mendelian inheritance, some polygenic inflammatory diseases like for example Crohn's disease clearly involve pathogenetic pathways shared with the monogenic auto-inflammatory syndromes. The investigators stipulate that this could also be the case in the Schnitzler syndrome for the following reasons: (1) this is a recurrent fever of unknown cause; (2) the peculiar eruption, characterized pathologically by a neutrophilic infiltrate very similar to the one observed in the auto-inflammatory cryopyrinopathies (CINCA/NOMID syndrome, Muckle-Wells syndrome and familial cold-urticaria); the investigators recently individualized this particular eruption, significantly associated with systemic inflammatory disease, within the group of neutrophilic urticarias (Kieffer et al. Medicine, in press); (3) the occurrence of aseptic neutrophilic osteitis, very similar to the one reported in patients with Majeed syndrome, another auto-inflammatory syndrome; (4) a significant increase of neutrophil count, not otherwise explained; (5) a spectacular response to the IL-1 inhibitor, within hours after the first injection, similar to what is reported in the PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome or the cryopyrinopathies, suggesting a direct pathogenic effect of IL-1.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2009

Longer than P75 for all trials

Geographic Reach
2 countries

17 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2009

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

July 3, 2009

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 7, 2009

Completed
8.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2017

Completed
Last Updated

September 8, 2017

Status Verified

September 1, 2017

Enrollment Period

8.2 years

First QC Date

July 3, 2009

Last Update Submit

September 7, 2017

Conditions

Keywords

Schnitzler syndromeWaldentsröm's diseaseanakinra

Study Arms (2)

A Patients with the Schnitzler syndrome

Patients with the Schnitzler syndrome

B Control subjects:

B1 healthy B2 other diseases

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

University hospitals

You may qualify if:

  • patients with the Schnitzler syndrome according to criteria established by Lipsker D et al. Medicine (Baltimore) 2001;80:37-44

You may not qualify if:

  • children and pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (17)

CHU de Besançon Service de Dermatologie

Besançon, France

Location

Service de DermatologieCHU Morvan5 avenue Foch

Brest, 29609, France

Location

Centre Hospitalier Général Bd Yves du Manoir

Dax, France

Location

Service de Rhumatologie Centre Hospitalier du Mans

Le Mans, 72037, France

Location

Service de Médecine Interne Hôpital Claude-Huriez

Lille, France

Location

Service de DermatologieHôtel Dieu

Lyon, 69288, France

Location

Service médecine interne et thérapeutique Hôpital sainte marguerite

Marseille, 13274, France

Location

Service de Dermatologie Hôpital Saint Eloi 80 avenue A Fliche

Montpellier, 34295, France

Location

Service de dermatologie CHU Hôtel Dieu1 place Alexis Ricordeau

Nantes, 44093, France

Location

Unité de médecine interne Centre Hospitalier G. Renon

Niort, 79021, France

Location

Service d'immuno-hématologie Hôpital St-Louis 1 av Claude Vellefaux

Paris, 75010, France

Location

Service de médecine interne Hôpital Tenon4, rue de la Chine

Paris, 75970, France

Location

Service de dermatologieCHU GUERIN2 rue de la Milétrie

Poitiers, 86021, France

Location

BOYE Thierry

Toulon, 83041, France

Location

Service de médecine interne-néphrologie Centre Hospitalier Valenciennes

Valenciennes, 59322, France

Location

Azienda Ospedaliero Universitaria Policlinico

Bari, 70122, Italy

Location

Clinica DermatologicaUnivesité de GênesVialle Benedetto

Genova, 716132, Italy

Location

Biospecimen

Retention: SAMPLES WITH DNA

White cells Serum

MeSH Terms

Conditions

Schnitzler Syndrome

Condition Hierarchy (Ancestors)

Monoclonal Gammopathy of Undetermined SignificanceParaproteinemiasImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Dan Lipsker, Pr

    HUS

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 3, 2009

First Posted

July 7, 2009

Study Start

July 1, 2009

Primary Completion

September 1, 2017

Study Completion

September 1, 2017

Last Updated

September 8, 2017

Record last verified: 2017-09

Locations